Drugs and Devices

April 2017 Vol. 12 No. 4

On April 11, the U.S. Food and Drug Administration (FDA) approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. It’s the first drug approved by the FDA for this condition.

The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive . . .

March 2017 Vol. 12 No. 3

On April 7, the U.S. Food and Drug Administration (FDA) approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Read more . . .

March 2017 Vol. 12 No. 3

On April 6, the U.S. Food and Drug Administration (FDA) announced it was allowing marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer genetic tests that the FDA as authorized. Read more . . .

March 2017 Vol. 12 No. 3

On March 28, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema. Read more . . .

March 2017 Vol. 12 No. 3

On March 21, the U.S. Food and Drug Administration (FDA) approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. Read more . . .

March 2017 Vol. 12 No. 3

17-alpha Hydroxyprogesterone caproate, commonly given to prevent recurrent preterm birth, is not effective for prevention and may increase the risk of gestational diabetes, according to a study in the American Journal of Obstetrics & Gynecology. Read more . . .

March 2017 Vol. 12 No. 3

More than half of older women with early stage breast cancer receive more radiation therapy than what might be medically necessary and following evidence-based guidelines for radiation would significantly reduce costs, according to a study in the Journal of Oncology Practice. Read more . . .

February 2017 Vol. 12 No. 2

On March 1, the U.S. Food and Drug Administration (FDA) approved Odactra, the first allergen extract to be administered sublingually to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in people 18 through 65 years of age. Read more . . .

February 2017 Vol. 12 No. 2

On Feb. 28, the U.S. Food and Drug Administration (FDA) approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. Read more . . .

February 2017 Vol. 12 No. 2

On Feb. 15, the U.S. Food and Drug Administration announced that Zimmer Biomet has recalled its Biomet Comprehensive Reverse Shoulder Humeral system because of a higher fracture rate. Read more

&nbsp . . .